Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Mylan N V's Business Segments
Mylan N V's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2020
Reportable Segments
4
Largest Segment
Europe
Total Revenue
$ 2,972
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2020
- Europe38.7%
- North America36.5%
- Rest of World31.1%
- Corporate and Unallocated0%
Revenue by Reportable Segment - Q3 FY2020
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 1,151 | 38.7% |
| North America | $ 1,086 | 36.5% |
| Rest of World | $ 925 | 31.1% |
Revenue by Product & Service Category - Q3 FY2020
- Respiratory & Allergy9.6%
- Central Nervous System and Anesthesia6.1%
- Oncology5.8%
- Women's Healthcare3.2%
- Diabetes & Metabolism2.4%
- Cardiovascular2%
- Other Therapeutic Franchises1.5%
- Gastroenterology1.4%
- Infectious Disease1.3%
- Dermatology1.1%
- Product and Service, Other0.8%
- Immunology0.3%
Revenue by Product & Service Category - Q3 FY2020
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Respiratory & Allergy | $ 285 | 9.6% |
| Central Nervous System and Anesthesia | $ 182 | 6.1% |
| Oncology | $ 171 | 5.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
9 more categories available
Sign in to unlock the full Mylan N V dataset.
Description of Mylan N V
Throughout its history, Mylan has been a leader in the United States generic pharmaceutical industry, as a result of its ability to efficiently obtain Abbreviated New Drug Application (ANDA) approvals and reliable high-quality supply chain. Mylan is now recognized as an industry leader globally, due to organic growth and transformative acquisitions since 2007, making it one of the largest generic and specialty pharmaceuticals companies in the world in terms of revenue. In July 2014, Mylan entered into a definitive agreement with Abbott to acquire Abbott’s non-U.S. developed markets specialty and branded generics business in an all-stock transaction. Mylan shareholders approved the transaction on January 29, 2015, and it closed on February 27, 2015, after receiving approval. As a result of the acquisition, Mylan N.V. has significantly expanded and strengthened its product portfolio in Europe, Japan, Canada, Australia, and New Zealand. Mylan now markets a global portfolio of approximately 1,400 different products covering a vast array of therapeutic categories, including antiretroviral therapies (ARVs), upon which approximately 40% of HIV/AIDS patients in developing countries depend. Mylan also operates one of the largest API manufacturers, supplying low cost, high quality API for its products and pipeline, as well as for a number of third parties.
Overview of Mylan N.V.
Mylan N.V. is a prominent global pharmaceutical company recognized for its expansive product offerings and diverse service segments. The organization is dedicated to providing high-quality, affordable medications to improve patient access and healthcare outcomes worldwide.
Segments
1. Generic Pharmaceuticals:
- Mylan is a leader in the production and distribution of generic pharmaceutical products. It has a vast portfolio covering a wide spectrum of therapeutic areas. The company specializes in developing and manufacturing various dosage forms, which include:
- Tablets: Solid oral dosage forms available in multiple strengths.
- Capsules: Both hard and soft gelatin capsules.
- Injectables: Including both sterile solutions and powders for reconstitution.
- Inhalers: Products designed for respiratory conditions, including metered-dose inhalers and nebulizers.
- Transdermal Patches: Systems for delivering medications through the skin for sustained release.
2. Specialty Pharmaceuticals:
- Mylan’s specialty pharmaceutical segment focuses on high-value therapies for complex conditions. This segment features products tailored to oncology, hepatitis, dermatology, ophthalmology, and HIV/AIDS treatment, often involving complex formulations and delivery methods.
3. Biosimilars:
- Mylan has made significant strides in biosimilars, which are bioengineered products similar to already approved biological therapies. This segment is vital for reducing treatment costs and improving access for patients with chronic illnesses, such as cancer and autoimmune disorders.
4. Contract Manufacturing:
- Utilizing its advanced manufacturing capabilities, Mylan offers contract manufacturing services to external pharmaceutical companies. This includes the development and production of a variety of pharmaceutical forms, thereby optimizing their operational efficiencies.
Products
Mylan’s extensive product range spans several therapeutic categories. Some key areas of focus include:
1. Oncology:
- A robust portfolio of treatments aimed at targeting various types of cancer, including chemotherapy agents and supportive care products.
2. Immunology:
- Medications for the management of autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, emphasizing patient-centered therapies.
3. CNS (Central Nervous System):
- A range of products addressing neurological disorders, including medications for epilepsy, Alzheimers disease, and other cognitive impairments.
4. Infectious Diseases:
- Antiretrovirals for HIV/AIDS, as well as treatments for hepatitis and tuberculosis, reflecting a commitment to combatting global health challenges.
5. Respiratory:
- Products designed for patients with asthma and COPD, including inhalation therapies that ease breathing difficulties.
6. Cardiovascular:
- A diverse range of medications for hypertension and other heart-related conditions, aimed at managing cardiovascular health effectively.
Services
1. Mylan Institutional:
- This segment provides specialized products and support tailored to hospitals, long-term care facilities, and other healthcare institutions. It focuses on delivering essential medicines that can meet the needs of patient populations in institutional settings.
2. Mylan Specialty:
- Dedicated to patients with complex and rare diseases, this division provides specialty therapies accompanied by comprehensive support services. Mylan Specialty emphasizes personalized care, including patient education and adherence programs to enhance treatment outcomes.
3. Mylan Global Supply Chain:
- This business unit ensures that Mylans products are produced efficiently and delivered in a timely manner. It manages all aspects of the supply chain, from raw materials to manufacturing and distribution, to optimize operational effectiveness while enhancing product availability to healthcare providers and patients globally.
Conclusion
Mylan N.V. plays a crucial role in the global pharmaceutical landscape by offering a wide array of segments, products, and services. The company’s commitment to quality, innovation, and affordability enhances its reputation as a leading player in the industry. Its ability to provide both generic and specialized medications, as well as contract manufacturing and comprehensive support services, positions Mylan as a key contributor to improved health outcomes on a global scale.
Mylan N.V. is a prominent global pharmaceutical company recognized for its expansive product offerings and diverse service segments. The organization is dedicated to providing high-quality, affordable medications to improve patient access and healthcare outcomes worldwide.
Segments
1. Generic Pharmaceuticals:
- Mylan is a leader in the production and distribution of generic pharmaceutical products. It has a vast portfolio covering a wide spectrum of therapeutic areas. The company specializes in developing and manufacturing various dosage forms, which include:
- Tablets: Solid oral dosage forms available in multiple strengths.
- Capsules: Both hard and soft gelatin capsules.
- Injectables: Including both sterile solutions and powders for reconstitution.
- Inhalers: Products designed for respiratory conditions, including metered-dose inhalers and nebulizers.
- Transdermal Patches: Systems for delivering medications through the skin for sustained release.
2. Specialty Pharmaceuticals:
- Mylan’s specialty pharmaceutical segment focuses on high-value therapies for complex conditions. This segment features products tailored to oncology, hepatitis, dermatology, ophthalmology, and HIV/AIDS treatment, often involving complex formulations and delivery methods.
3. Biosimilars:
- Mylan has made significant strides in biosimilars, which are bioengineered products similar to already approved biological therapies. This segment is vital for reducing treatment costs and improving access for patients with chronic illnesses, such as cancer and autoimmune disorders.
4. Contract Manufacturing:
- Utilizing its advanced manufacturing capabilities, Mylan offers contract manufacturing services to external pharmaceutical companies. This includes the development and production of a variety of pharmaceutical forms, thereby optimizing their operational efficiencies.
Products
Mylan’s extensive product range spans several therapeutic categories. Some key areas of focus include:
1. Oncology:
- A robust portfolio of treatments aimed at targeting various types of cancer, including chemotherapy agents and supportive care products.
2. Immunology:
- Medications for the management of autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, emphasizing patient-centered therapies.
3. CNS (Central Nervous System):
- A range of products addressing neurological disorders, including medications for epilepsy, Alzheimers disease, and other cognitive impairments.
4. Infectious Diseases:
- Antiretrovirals for HIV/AIDS, as well as treatments for hepatitis and tuberculosis, reflecting a commitment to combatting global health challenges.
5. Respiratory:
- Products designed for patients with asthma and COPD, including inhalation therapies that ease breathing difficulties.
6. Cardiovascular:
- A diverse range of medications for hypertension and other heart-related conditions, aimed at managing cardiovascular health effectively.
Services
1. Mylan Institutional:
- This segment provides specialized products and support tailored to hospitals, long-term care facilities, and other healthcare institutions. It focuses on delivering essential medicines that can meet the needs of patient populations in institutional settings.
2. Mylan Specialty:
- Dedicated to patients with complex and rare diseases, this division provides specialty therapies accompanied by comprehensive support services. Mylan Specialty emphasizes personalized care, including patient education and adherence programs to enhance treatment outcomes.
3. Mylan Global Supply Chain:
- This business unit ensures that Mylans products are produced efficiently and delivered in a timely manner. It manages all aspects of the supply chain, from raw materials to manufacturing and distribution, to optimize operational effectiveness while enhancing product availability to healthcare providers and patients globally.
Conclusion
Mylan N.V. plays a crucial role in the global pharmaceutical landscape by offering a wide array of segments, products, and services. The company’s commitment to quality, innovation, and affordability enhances its reputation as a leading player in the industry. Its ability to provide both generic and specialized medications, as well as contract manufacturing and comprehensive support services, positions Mylan as a key contributor to improved health outcomes on a global scale.